The company is planning to submit a BLA for brelovitug in chronic HDV in the first half of 2027.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta ...

By Sneha S K Sept 28 (Reuters) - Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study. Here are ...

Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...

US rare disease company Mirum Pharmaceuticals (Nasdaq: MIRM) said Monday that its experimental antibody brelovitug met the ...

The Phase 3 AZURE-1 study evaluated Brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg). The trial achieved its primary endpoint of ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy ...

(Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, ...

Accurate detection and quantification of hepatitis delta virus (HDV) RNA are essential for diagnosis, prognosis and treatment monitoring. This study aimed to evaluate whether thermal shock ...